ReCor Medical
Medical technology company focused on development, clinical validation, and commercialization of a catheter-based ultrasound renal denervation therapy for treatment of uncontrolled and resistant hypertension. Activities described on the site include randomized sham-controlled clinical trials, real-world registry and post-approval studies, regulatory approvals (FDA, CE, Japan), reimbursement engagement with CMS, investigator-sponsored research and educational support, and device design features intended to protect the renal artery during ultrasound ablation.
Industries
Nr. of Employees
small (1-50)
ReCor Medical
1049 Elwell Court, Palo Alto, CA 94303, USA
Patents
Method and apparatus for treatment of hypertension through percutaneous ultrasound renal denervation
US-12274833-B2
View DetailsIntraluminal microneurography denervation probe with radio frequency ablation
US-12161470-B2
View Details
Method and apparatus for treatment of hypertension through percutaneous ultrasound renal denervation
US-12274833-B2
View DetailsIntraluminal microneurography denervation probe with radio frequency ablation
US-12161470-B2
View DetailsProducts
Ultrasound renal denervation catheter system
A catheter-based system designed to deliver circumferential ultrasound energy to renal nerves via the main renal arteries using brief sonication bursts and an integrated coolant circulation system to protect the arterial wall.
Ultrasound renal denervation catheter system
A catheter-based system designed to deliver circumferential ultrasound energy to renal nerves via the main renal arteries using brief sonication bursts and an integrated coolant circulation system to protect the arterial wall.
Services
Financial and/or material support for investigator-initiated clinical studies with multi-step review and contractual award process.
Provision of procedural videos, webinars, symposium recordings, and clinical evidence presentations to support clinician education on renal denervation therapy.
Financial and/or material support for investigator-initiated clinical studies with multi-step review and contractual award process.
Provision of procedural videos, webinars, symposium recordings, and clinical evidence presentations to support clinician education on renal denervation therapy.
Expertise Areas
- Renal denervation therapy development
- Randomized, sham-controlled clinical trials
- Real-world evidence generation and registry studies
- Regulatory approvals and market access
Key Technologies
- 360-degree intravascular ultrasound energy delivery
- Balloon catheter coolant (hydro-cooling) systems
- Short-duration ultrasound sonication protocols
- Catheter-based endovascular ablation
News & Updates
First US site enrolled and treated patients in the US GPS post-approval study to collect real-world long-term safety and effectiveness data up to five years in up to 1,000 patients.
CMS published a Final Rule approving NTAP for the ultrasound renal denervation system for hospital inpatient procedures, providing additional reimbursement beginning Oct 1, 2024.
Device received U.S. regulatory approval in November 2023 for use as an adjunctive treatment to reduce blood pressure in indicated patients.
CMS issued a National Coverage Determination recognizing renal denervation, extending Medicare coverage for the therapy.
Results from the Global Paradise System (GPS) Registry showed a 19.6 mmHg reduction in office systolic blood pressure at six months in a cohort presented at TCT 2025.
Company announced regulatory authorization in Japan for manufacturing and marketing of the renal denervation system for treatment of resistant hypertension.
First US site enrolled and treated patients in the US GPS post-approval study to collect real-world long-term safety and effectiveness data up to five years in up to 1,000 patients.
CMS published a Final Rule approving NTAP for the ultrasound renal denervation system for hospital inpatient procedures, providing additional reimbursement beginning Oct 1, 2024.
Device received U.S. regulatory approval in November 2023 for use as an adjunctive treatment to reduce blood pressure in indicated patients.
CMS issued a National Coverage Determination recognizing renal denervation, extending Medicare coverage for the therapy.
Results from the Global Paradise System (GPS) Registry showed a 19.6 mmHg reduction in office systolic blood pressure at six months in a cohort presented at TCT 2025.
Company announced regulatory authorization in Japan for manufacturing and marketing of the renal denervation system for treatment of resistant hypertension.